Biohub, the nonprofit organisation backed by Mark Zuckerberg and Priscilla Chan, is coordinating a $1.8 billion initiative to build AI models that predict cell behaviour. This effort combines data sharing, laboratory equipment, and computing power to accelerate drug development. Meta, Google DeepMind, and Isomorphic Labs contribute $300 million, while the US Department of Energy invests over $500 million in measurements and compute. The National Institutes of Health will coordinate datasets built with previous federal funding, which Biohub will standardise for AI training. Commercial funders receive one year of exclusive access to their paid data before it becomes public, whereas government-funded work remains unrestricted. A first dataset is expected within a year.
The project matters because accurate cellular prediction could significantly shorten the timeline for discovering new medicines. Standardising data across different institutions reduces the friction researchers face when sharing findings. Private sector exclusivity ensures companies can recoup investment costs before the wider scientific community accesses the information. This approach mirrors similar moves by Anthropic and the OpenAI Foundation, which are also investing heavily in biological datasets.
- Commercial partners get one year of exclusive data access
- Government-funded research remains open to the public
- First dataset arrives in approximately twelve months
